The extension of this study can provide more detailed information about the role of PARP1 and caspases in several subsets of patients, based on their genetic profile, and could help formulate a plan about the possible use of PARP1 inhibitors in CLL. The gene discussed is PARP1; the disease is B-cell chronic lymphocytic leukemia.